{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/elexacaftor",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   atorvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bosentan\" outputclass=\"int-drug\">bosentan</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   bosentan .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">Crizotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Crizotinib   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fexofenadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glibenclamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"grapefruit\" outputclass=\"int-drug\">Grapefruit</ph> <ph outputclass=\"int-substanceQualifier\">juice</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Grapefruit   juice   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Grapefruit</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Imatinib   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"netupitant\" outputclass=\"int-drug\">Netupitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Netupitant   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Netupitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">Nilotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nilotinib   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pravastatin\" outputclass=\"int-drug\">pravastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   pravastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pravastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   repaglinide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Repaglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifabutin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decreases   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   simvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/elexacaftor#bnf_i1643857958383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-heading-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor-and-elexacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221286\">tezacaftor with ivacaftor and elexacaftor</xref> dose with potent CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   elexacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor and elexacaftor  dose with potent CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				}
			],
			"hasSearchLabel": " Elexacaftor  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/elexacaftor.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Elexacaftor </title>"
			},
			"rdfs:label": "elexacaftor"
		}
	]
}